[HTML][HTML] Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study
M Reck, N van Zandwijk, C Gridelli, Z Baliko… - Journal of Thoracic …, 2010 - Elsevier
Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
[引用][C] Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study
M Reck, N van Zandwijk, C Gridelli, Z Baliko… - Journal of Thoracic …, 2010 - cir.nii.ac.jp
Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global
Phase IV Tarceva Lung Cancer Survival Treatment Study | CiNii Research CiNii 国立情報学 …
Phase IV Tarceva Lung Cancer Survival Treatment Study | CiNii Research CiNii 国立情報学 …
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study
M Reck, N van Zandwijk, C Gridelli… - Journal of thoracic …, 2010 - pubmed.ncbi.nlm.nih.gov
Introduction Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
[PDF][PDF] Erlotinib in Non-small Cell Lung Cancer. Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study
M Reck, N van Zandwijk, C Gridelli… - Journal of Thoracic …, 2010 - oncologiatoracica.it
In base ai dati dell'edizione VII del TNM, la mediana di sopravvivenza dei pazienti con
tumore polmonare non a piccole cellule (NSCLC) è di 10 mesi allo stadio clinico IIIB, e di …
tumore polmonare non a piccole cellule (NSCLC) è di 10 mesi allo stadio clinico IIIB, e di …
[PDF][PDF] Erlotinib in Non-small Cell Lung Cancer. Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study
M Reck, N van Zandwijk, C Gridelli, Z Baliko… - Journal of Thoracic …, 2010 - academia.edu
In base ai dati dell'edizione VII del TNM, la mediana di sopravvivenza dei pazienti con
tumore polmonare non a piccole cellule (NSCLC) è di 10 mesi allo stadio clinico IIIB, e di …
tumore polmonare non a piccole cellule (NSCLC) è di 10 mesi allo stadio clinico IIIB, e di …
[HTML][HTML] Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study
M Reck, N van Zandwijk, C Gridelli, Z Baliko… - Journal of Thoracic …, 2010 - jto.org
Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
M Reck, N van Zandwijk, C Gridelli, Z Baliko… - Journal of Thoracic …, 2010 - europepmc.org
Methods Patients who had previously failed on chemotherapy or radiotherapy and were
unsuitable for these treatments were treated with oral erlotinib (150 mg/d) until disease …
unsuitable for these treatments were treated with oral erlotinib (150 mg/d) until disease …
[PDF][PDF] Erlotinib in Advanced Non-small Cell Lung Cancer
M Reck, MD Nico van Zandwijk, C Gridelli… - Journal of Thoracic …, 2010 - core.ac.uk
Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global
Phase IV Tarceva Lung Cancer Surviv Page 1 ORIGINAL ARTICLE Erlotinib in Advanced …
Phase IV Tarceva Lung Cancer Surviv Page 1 ORIGINAL ARTICLE Erlotinib in Advanced …